Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Doctors Should Push HPV Vaccine for Cancer Prevention, Says CDC

XTALKS VITALS NEWS

Vaccine

The HPV vaccine is targeted towards kids between the ages of 11 and 12, as way to prevent them from contracting and spreading the virus – which has been linked to cases of cervical cancer – before they become sexually active.

Tweetables from this article:

Tweet: Only 40 percent of girls and 21 percent of boys received the #HPV shot last year http://ctt.ec/LRbEQ+ Only 40 percent of girls and 21 percent of boys received the HPV shot last year.

Share this!

October 21, 2016 | by Sarah Hand, M.Sc.

To increase the number of kids getting vaccinated against Human Papilloma Virus (HPV), the Centers For Disease Control and Prevention (CDC) is encouraging doctors to emphasize the shot as a form of cancer prevention, rather than STD protection. Drugmakers and public health workers hope that this tactic could convince skeptical parents to get their children vaccinated.

The HPV vaccine is targeted towards kids between the ages of 11 and 12, as way to prevent them from contracting and spreading the virus – which has been linked to cases of cervical cancer – before they become sexually active. But some parents are hesitant to get their kids vaccinated, saying their children are too young to be thinking about STD protection.

Both companies which manufacture approved versions of the HPV vaccine – Merck & Co. and GlaxoSmithKline – have seen slow uptake of the vaccines since their launch on the market. Shying away from the STD protection aspects of the vaccine, Merck recently launched a new commercial for their HPV vaccine, Gardasil, which highlights the cancer prevention abilities of the shot.



Safety concerns surrounding the HPV vaccine and the anti-vaccines movement have also impacted the number of kids getting the shot. While the U.S. Department of Health and Human Services has a set a target of vaccinating 80 percent of boys and girls by 2020, only 40 percent of girls and 21 percent of boys received the HPV shot last year.

While the HPV vaccine currently requires a course of three shots over a six month period, public health officials are considering reducing that number to two. If approved by the CDC, the two-dose schedule could make it easier for kids to get the HPV vaccine.

Approximately 14 million people in the US become infected with HPV each year, and up to 25 percent of the entire population is already infected, according to the CDC. The disease is asymptomatic in most people, but 30,700 cases of cancer – including cervical, penile and throat – are attributed to HPV infection, each year.


Keywords: Vaccine, Cancer, CDC


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.